Crystec are honoured to have been awarded the Making Pharmaceuticals Award for Innovation in Manufacturing. The award was presented for Crystec’s mSAS® (modified Supercritical Anti-Solvent) technology and chosen from shortlisted companies including kg-pharma, iDi Pac, Glatt Protech and SSPC, Bernal Institute.
Crystec’s CEO, Paul Thorning, has contributed to an article by UBM featuring the big issues affecting Pharma for 2019, according to key opinion leaders in the industry. Contributors include representatives from PharmSource, Catalent Pharma Solutions and NIBRT.
Crystec are delighted to have been selected as finalists for the CPhI Excellence in Pharma Awards for the second year running. Having been awarded CPhI Excellence in Pharma for Contract Services and Outsourcing in 2017, we are delighted that our applications have progressed to the final selection stage.
Crystec are delighted to have been awarded the CPhI Excellence in Pharma Award for Contract Services and Outsourcing. The award was presented for Crystec’s modified supercritical anti-solvent (mSAS) technology for accelerated product development, and chosen from shortlisted companies including 3M, Alcami, Catalent Pharma Services and Merck.